BackAlto Neuroscience Overview

Alto Neuroscience Current Cash

Alto Neuroscience's current cash is $260M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$263.76M
↑ 64.08% YoYΔ $103.01M vs prior year quarter

Peer average

Loading

Alto Neuroscience Current Cash History

Loading

Alto Neuroscience vs. peers: Current Cash Comparison

Loading

Alto Neuroscience Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Alto Neuroscience (ANRO) FAQ

The latest current cash for ANRO is $260M as of March 2026. That compares with $160M in the prior-year period — up 64.1% year over year. Investors often review this figure alongside Alto Neuroscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, ANRO's current cash moved from $160M to $260M — a 64.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Alto Neuroscience's operating scale or balance-sheet position.

A current cash figure of $260M for ANRO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ANRO's current cash ($260M), review year-over-year change from $160M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.